Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related...

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Graft-vs.-host disease (GVHD) and infections are significant complications following allogeneic bone marrow transplantation.
• Previous studies suggested intravenous immunoglobulin (IVIg) at 500 mg/kg/wk could reduce acute GVHD, pneumonia, and infection post-transplant.

Purpose of the Study:

• To evaluate if a reduced total dose of IVIg, combined with pretransplant loading, decreases transplant-related complications in adult patients undergoing allogeneic bone marrow transplantation.

Main Methods:

• A randomized controlled trial involving 241 adult patients receiving related donor marrow allografts.
• Patients received either IVIg prophylaxis (loading dose followed by maintenance) or no IVIg (control group).
• Stratification by HLA-matching, malignancy remission, GVHD prophylaxis, and CMV serology.

Main Results:

• IVIg prophylaxis did not significantly reduce the incidence of acute GVHD, CMV infection, interstitial pneumonia, or bacteremia.
• While not statistically significant, acute GVHD was less frequent in patients achieving very high IgG levels (>3000 mg/dL).
• The cumulative incidence of malignancy relapse was higher in the IVIg group (31% vs. 18%), indicating an increased risk of relapse with IVIg.

Conclusions:

• Pretransplant loading with a lower total dose and shorter duration of IVIg prophylaxis did not decrease acute GVHD or mortality in adult related donor marrow transplant recipients.
• IVIg administration in this context may be associated with an increased risk of malignancy relapse, warranting further investigation.